Bristol-Myers Squibb Co. (BMY) Valuation
Historical valuation analysis based on 1280 data points (2021-09-13 to 2026-10-16)
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where th...
Bristol-Myers Squibb Co. (BMY) currently trades at a P/E ratio of 13.15 (historical range: 12.04–27.71, median: 18.43), placing it at the 12th percentile — cheap relative to its history, P/S ratio of 2.48 (range: 1.73–3.74, 45th percentile — near its historical average), EV/EBITDA of 12.18 (range: 10.30–167.93, 26th percentile).
Over the historical period (2021-09-13 to 2026-10-16), Bristol-Myers Squibb Co.'s P/E ratio has contracted by 14% over the observed period (from an average of 19.9 to 17.1).
Bristol-Myers Squibb Co. trades below its historical valuation range, with most metrics below their median levels.
Historical Valuation Metrics
| Metric | Current | Median | %ile | Assessment |
|---|---|---|---|---|
| P/E Ratio | 13.15 | 18.43 | 12th | cheap relative to its history |
| P/S Ratio | 2.48 | 2.54 | 45th | near its historical average |
| EV/EBITDA | 12.18 | 15.86 | 26th | below its historical average |
| FCF Yield | 9.37% | 10.76% | 34th | above its historical average |
Bristol-Myers Squibb Co. (BMY) Valuation & P/E History
Bristol-Myers Squibb Co. (BMY) is a US-listed stock operating in the Healthcare sector, specifically the Drug Manufacturers - General industry currently trading at $60.19 with a market capitalization of $123.0 billion. This page provides historical valuation analysis for BMY based on 1280 data points covering 2021-09-13 to 2026-10-16. The P/E ratio of 13.15 is below the historical median of 18.43, placing BMY at the 12th percentile of its valuation range. The P/S ratio of 2.48 compares to a median of 2.54.
BMY Valuation Metrics & Historical Range
The valuation table above shows Bristol-Myers Squibb Co.'s current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether BMY is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests BMY is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Bristol-Myers Squibb Co..
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is BMY Overvalued or Undervalued?
Bristol-Myers Squibb Co. trades below its historical valuation range, with most metrics below their median levels. The overall valuation percentile of 28 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive BMY is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full BMY analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.BMY trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.